Acute Respiratory Distress Syndrome (ARDS) Clinical Trial
Official title:
Influence of Quality of Care and Individual Patient Characteristics on Quality of Life/ Return to Work in Survivors of the Acute Respiratory Distress Syndrome (ARDS): Prospective, Observational, Multi-centre Cohort Study
The purpose of the DACAPO study ("Surviving ARDS: the influence of quality of care and
individual patient characteristics on quality of life") is to investigate the role of
quality of care and individual patient characteristics on quality of life and return to work
in survivors of ARDS (acute respiratory distress syndrome). It is hypothesized that higher
quality of care is associated with better health-related quality of life and a higher rate
of return to work among survivors.
A prospective, observational, multi-centre patient cohort study is performed in Germany,
using hospitals from the "ARDS Network Germany" as the main recruiting centres. It is
envisaged to recruit 2400 patients into the DACAPO study and to analyze a study population
of 1500 survivors. They will be followed up until 12 months after discharge from hospital.
Quality of care will be assessed as process quality, structural quality and volume at the
institutional level. The main outcomes (health related quality of life and return to work)
will be gathered by self-report questionnaires. Further data assessment includes general
medical and ARDS-related characteristics of patients as well as sociodemographic and
psycho-social parameters. Multilevel hierarchical modelling will be performed to analyse the
effects of quality of care and individual patient characteristics on outcomes, taking the
cluster structure of the data into account.
Design Patients will be included in the study at the beginning of ICU stay in a
participating hospital (t0) and survivors will be followed over a period of 12 months after
discharge from ICU. If patients have been treated before in a referring hospital, a
retrospective assessment of their health status during their stay in this hospital and
during inter-hospital transport will be performed. Four follow-up measurements (at discharge
from ICU as well as 3, 6 and 12 months after discharge) will be performed on individual
patient level.
Sample & Recruitment Hospitals of the "ARDS Network Germany" and other hospitals which
provide care for patients with ARDS were invited to participate in the study.
It is envisaged to screen 2600 patients for the presence of ARDS and to include 2400
patients as members of the source population. An in-hospital mortality rate of 30% is
assumed; therefore, we expect to analyze a study population of 1500 patients at t1
(discharge from ICU). For each follow-up-assessment (t2-t4: 3 months, 6 months, 12 months
after discharge), loss-to-follow-up rates due to death, withdrawal of consent or other
reasons are estimated to be about 10%, resulting in slightly more than 1000 patients at
12-months-follow-up.
Measurements The main predictor is quality of care provided in the ICUs of the participating
hospitals. The following main indicators were chosen: qualification of physicians,
implementation of routine daily multiprofessional ward rounds with documentation of daily
therapy goals, number of ventilated patients per, and membership of the hospital in the
"ARDS Network Germany". All quality indicators will be assessed by questionnaire at the
institutional level.
Main outcome measures of the DACAPO study are HRQoL and return to work among survivors of
ARDS (see study outcomes).
Moderating variables are gender, socio-economic status, prevalent and incident
psychopathological symptoms (PHQ-D, PTSS-14) and the availability of social support (F-SozU
K-14).
Additional variables comprise general medical ICU parameters (e.g. comorbidity, prognostic
scores (SAPS (Simplified Acute Physiology Score) II, SAPS III ) and an organ dysfunction
score (SOFA (Sequential Organ Failure Assessment score)) and parameters relating to ARDS
(e.g. cause and severity) and its treatment (e.g. ventilation parameters, use of supportive
care measures, critical events (hypoglycaemia, hypoxia)) as well as socio-demographic and
psycho-social characteristics.
Additionally, costs will be assessed as direct costs in terms of treatment costs at the ICU.
Data Sources and Data Collection Patients's general medical characteristics and medical data
relating to ARDS and its treatment will be assessed during ICU stay and gathered through
electronic case report forms (eCRFs). Data on the direct costs of treating patients with
ARDS in the ICU will be gathered from hospital records. A 12-months mortality follow-up will
be performed. Local municipal population registries will be contacted to obtain data on
mortality at the patient level.
At baseline, caregivers will provide proxy report of patients' socio-demographic data, at
follow-ups (discharge from ICU, 3 months, 6 months, 12 months), patients themselves will
complete self-report questionnaires on socio-demographic and psycho-social characteristics
as well as on the main outcome measures.
Data on indicators of quality of care will be assessed through questionnaires administered
to the directors of the hospitals/ICUs.
Data Management The open source software OpenClinica, version 3.1, will be used for
electronic data collection and data management. eCRFs will be used for data entry. A
continuous assessment of data quality will be performed by exporting data sets to
statistical packages to run further error and plausibility checks. Data from
paper-pencil-questionnaires completed by patients will be entered into the database twice in
order to ensure high data quality.
Statistical Analysis A linear multilevel regression model will be fitted both for the
physical and the mental component summary score of the SF-12. A non-parametric multilevel
regression model will be used for the outcome "return to work". The modelling procedure will
be applied to each of the operationalizations of the predictor "quality of care".
All analyses will be carried out using SAS 9.4 software and STATA version 12 software.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03909854 -
Pragmatic Investigation of Volume Targeted Ventilation-1
|
N/A | |
Completed |
NCT02288949 -
Stratification of the Acute Respiratory Distress Syndrome
|
||
Recruiting |
NCT02574169 -
Alveolar Recruitment Maneuvers, Intracerebral Hemodynamic and Oxygenation
|
N/A | |
Completed |
NCT04548739 -
Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
|
||
Completed |
NCT05024500 -
Clinical and Functional Outcomes of Critically Ill Patients With COVID-19
|
N/A | |
Terminated |
NCT04511650 -
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
|
Phase 2 | |
Recruiting |
NCT01339533 -
Airway Pressure Release Ventilation (APRV) Versus AC/VC Conventional Ventilation
|
Phase 2 | |
Active, not recruiting |
NCT01274260 -
Trial of Steroids in Pediatric Acute Lung Injury/ARDS
|
Phase 2 | |
Recruiting |
NCT03296059 -
Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates
|
N/A | |
Terminated |
NCT04609865 -
Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia
|
Phase 3 | |
Active, not recruiting |
NCT04009330 -
Clinical Evaluation of a Point of Care (POC) Assay to Identify Phenotypes in the Acute Respiratory Distress Syndrome
|
||
Not yet recruiting |
NCT05847517 -
Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN)
|
Phase 3 | |
Not yet recruiting |
NCT06127381 -
An Open-label Study of the Safety and Pharmacokinetics of the TGKP
|
Phase 1 | |
Completed |
NCT01854424 -
Validation of the Percentage of Alveolar Fibrocyte as Biomarker During ARDS
|
N/A | |
Completed |
NCT03870009 -
Validation of a Semi-automatized Method to Detect Cyclic Hyperinflation on CT-scan in ARDS
|
N/A | |
Completed |
NCT04311697 -
Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure
|
Phase 2/Phase 3 | |
Recruiting |
NCT02095444 -
Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection
|
Phase 1/Phase 2 | |
Recruiting |
NCT04460859 -
RecruitmEnt Assessed by eleCtRical Impedance Tomography
|
||
Completed |
NCT01926093 -
Low Dose Lung CT Scan for Quantitative Analysis in ARDS Patients
|
N/A | |
Terminated |
NCT01506401 -
The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial
|
Phase 3 |